[{"address1": "4224 Campus Point Court", "address2": "Suite 210", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 202 6300", "website": "https://www.regulusrx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joseph P. Hagan M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 920728, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Crispina  Calsada CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 500866, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher Ray Aker J.D.", "age": 62, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 524790, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Preston S. Klassen M.D., M.H.S.", "age": 54, "title": "President, Head of Research & Development and Director", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Penksa", "age": 37, "title": "VP of Finance & Controller", "yearBorn": 1986, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Claire Susan Padgett M.S., M.T., Ph.D.", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rekha  Garg M.D., M.S.", "title": "Senior Vice President of Clinical Development & Regulatory", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Lee Ph.D.", "title": "Vice President of Translational Medicine", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.67, "open": 2.65, "dayLow": 2.614, "dayHigh": 2.77, "regularMarketPreviousClose": 2.67, "regularMarketOpen": 2.65, "regularMarketDayLow": 2.614, "regularMarketDayHigh": 2.77, "beta": 1.444, "forwardPE": -4.4262295, "volume": 220505, "regularMarketVolume": 220505, "averageVolume": 3129577, "averageVolume10days": 570880, "averageDailyVolume10Day": 570880, "bid": 2.69, "ask": 2.74, "bidSize": 100, "askSize": 400, "marketCap": 176756320, "fiftyTwoWeekLow": 0.88, "fiftyTwoWeekHigh": 3.79, "fiftyDayAverage": 1.9062, "twoHundredDayAverage": 1.50805, "currency": "USD", "enterpriseValue": 167879920, "floatShares": 41551449, "sharesOutstanding": 65465300, "sharesShort": 5129655, "sharesShortPriorMonth": 96995, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.0784, "heldPercentInsiders": 0.0141199995, "heldPercentInstitutions": 0.43627, "shortRatio": 0.6, "shortPercentOfFloat": 0.0842, "bookValue": 1.047, "priceToBook": 2.5787964, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -30037000, "trailingEps": -1.58, "forwardEps": -0.61, "pegRatio": -0.12, "lastSplitFactor": "1:12", "lastSplitDate": 1538611200, "enterpriseToEbitda": -5.436, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RGLS", "underlyingSymbol": "RGLS", "shortName": "Regulus Therapeutics Inc.", "longName": "Regulus Therapeutics Inc.", "firstTradeDateEpochUtc": 1349789400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cd43addf-be3b-3da4-8113-29f5cb221300", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.7, "targetHighPrice": 11.0, "targetLowPrice": 2.0, "targetMeanPrice": 6.2, "targetMedianPrice": 6.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 23767000, "totalCashPerShare": 0.363, "ebitda": -30882000, "totalDebt": 3102000, "quickRatio": 2.793, "currentRatio": 3.312, "debtToEquity": 14.641, "returnOnAssets": -0.50198, "returnOnEquity": -1.10272, "freeCashflow": -16934624, "operatingCashflow": -26768000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-10"}]